Search PubMed⌕ Search

Biomedical subjects

N D Grace

Publications and source records attributed to N D Grace.

At least 37 records · Page 2Linked to original sources

Trace element metabolism, dietary requirements, diagnosis and prevention of deficiencies in deer.

The first deer farms were established in New Zealand about 30 years ago. Extensive studies on trace elements in sheep and cattle have resulted in clarification of the requirements of those species and the development of protocols to diagnose and prevent deficiencies. In contrast, there have been very few studies conducted with deer. This review summarises information available on trace element nutrition of deer and concludes that, in New Zealand, cobalt (Co), vitamin B12, selenium (Se) and iodine (I) deficiencies are of lesser importance than copper (Cu), which can have a significant impact on deer health and performance. However, on individual farms, Se and I deficiency may cause significant production losses if not managed appropriately. There are no reports of production limitations caused by Co deficiency. Copper deficiency manifests itself as clinical disease, namely enzootic ataxia and osteochondrosis. Growth responses to Cu supplementation have only been reported in 2/11 trials and were not predicted from low serum and/or liver Cu concentrations. On the basis of clinical signs of Cu deficiency, the proposed reference ranges used to predict Cu status from serum Cu concentrations (micromol/l) are: 5, deficient; 5-8, marginal and; 8, adequate; and for liver Cu concentrations (micromol/kg fresh tissue) are: 60, deficient; 60-100, marginal and; 100, adequate. Copper supplementation strategies based on Cu-EDTA injections, Cu-oxide needles or the application of Cu to pasture are effective at increasing Cu status for varying periods. More recent research suggests that alternative forage species that have a high Cu content (10 mg/kg dry matter (DM), may play a role in the prevention of Cu deficiency.

Journal Article↗

Pharmacologic therapy for portal hypertension.

Pharmacologic therapy for portal hypertension is effective in the treatment and prevention of hemorrhage from esophagogastric varices. Acute hemorrhage from varices can be treated with intravenous agents such as somatostatin or terlipressin, either alone or in combination with endoscopic sclerotherapy or band ligation. Intravenous octreotide has not shown effectiveness as monotherapy, but it appears to be beneficial when combined with endoscopic treatment. The prevention of rebleeding after initial hemorrhage is best accomplished with non-selective beta blockers, endoscopic band ligation of varices, or a combination of endoscopic and pharmacologic therapies. The addition of oral nitrates may further decrease rebleeding rates, but more data from randomized trials are needed. Beta blockers are currently the only agents recommended for the primary prevention of variceal hemorrhage.

Acute Disease↗

Primary prophylaxis of variceal hemorrhage.

Figure 3 shows an algorithm for the primary prevention of variceal hemorrhage. Pharmacologic therapy is the current standard of treatment for the primary prophylaxis of esophageal variceal bleeding. Patients with medium or large varices should be treated with a nonselective beta-blocker with the dose titrated to achieve a 25% decrement in resting heart rate or a heart rate of 55 to 60 bpm. The development of symptoms will, of course, limit the dose used. As discussed previously, these therapeutic endpoints are not well correlated with decreases in portal pressure. Measurement of the HVPG before therapy and after 3 months of therapy provides a rational approach to drug dosing. If the HVPG decreases by 20% or to less than 12 mm Hg, the medication dose will be effective in preventing hemorrhage. If, however, the HVPG is not appropriately lowered, a long-acting nitrate may be added. Patients with small varices should be observed, with endoscopic examinations every 2 years to assess progression of variceal size. Endoscopic therapy is not indicated for the primary prevention of variceal bleeding.

Adrenergic beta-Antagonists↗

Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?

Although beta blockers have had significant impact in the treatment of portal hypertension, the question of how long they should be continued for prevention of variceal hemorrhage remains unknown. Prospective studies on beta blockers to prevent variceal hemorrhage lack long-term follow-up, and indefinite administration of beta blockers for primary prevention of variceal bleeding has become standard practice. The aim of this study was to determine the outcomes of patients in whom beta blocker therapy was discontinued. Patients completing a prospective, randomized, double-blind, placebo-controlled trial of propranolol for the primary prevention of variceal hemorrhage were tapered off of propranolol and placebo and followed prospectively for subsequent events. Of the 49 patients in the follow-up study (25 former propranolol, 24 former placebo), 9 experienced variceal hemorrhage (6 former propranolol, 3 former placebo). Following withdrawal of propranolol, the freedom from variceal bleeding was not significantly different between these 2 groups of patients, suggesting that the protective effect of propranolol against variceal hemorrhage, noted previously, was no longer present. Seventeen patients died (12 former propranolol, 5 former placebo) during the follow-up study. Cumulative survival was longer in the placebo group. These trends for EVH and survival were opposite to those observed in the original study population while patients were taking medication. When propranolol is withdrawn, the risk of variceal hemorrhage returns to what would be expected in an untreated population. Patients who discontinue beta blockers experience increased mortality compared with an untreated population. These observations support the current practice of indefinite prophylactic therapy.

Adrenergic beta-Antagonists↗

Relationship between blood selenium concentration or glutathione peroxidase activity, and milk selenium concentrations in New Zealand dairy cows.

AIM: To determine the relationships between blood selenium (Se) concentrations or glutathione peroxidase activity (GSH-Px), and milk Se concentrations in dairy cows. METHODS: Seventy-two Friesian dairy cows were either untreated or injected with 0.5, 1.0 or 2.0 mg Se/kg liveweight as barium selenate (BaSeO4) formulations, resulting in 6 groups of animals with mean blood Se concentrations that varied from 212 to 2272 nmol/l. Milk samples were collected on Days 104 and 188, and blood samples were collected prior to treatment and on Days 41, 76, 104, 188, 244, and 292 after Se injection. RESULTS: Significant quadratic relationships between blood Se and milk Se concentrations, as well as blood GSH-Px activity and milk Se concentrations, were evident at Days 104 and 188. Using combined data, these were represented by the equations: milk Se = 27.3 + 0.073 blood Se -0.00001 (blood Se)2; R2=0.79, p<0.005, and; milk Se = 34.8 + 4.99 GSH-Px -0.068 (GSHPx)2; R2=0.79, p<0.005. CONCLUSIONS: The Se status of dairy cows can be assessed from milk Se concentrations. CLINICAL SIGNIFICANCE: Bulk-tank milk Se concentrations could be evaluated as a method to assess the Se status of dairy herds.

Journal Article↗

A review of tissue reference values used to assess the trace element status of farmed red deer (Cervus elaphus).

AIMS: This paper reviews the principles for the establishment of biochemical reference criteria for assessing the trace element status of farmed livestock and summarises data for copper, selenium, vitamin B12 and iodine for farmed red deer. COPPER: Enzootic ataxia and osteochondrosis occur when liver copper concentrations are below 60 micromol/kg fresh tissue, and serum copper concentrations are below 3-4 micromol/l. Growth responses to copper supplementation have been equivocal when blood copper concentrations were 3-4 micromol/l, but were significant when mean blood copper concentrations were 0.9-4.0 micromol/l. No antler growth or bodyweight response to copper supplementation was observed when blood ferroxidase levels averaged 10-23 IU/l (equivalent to serum copper concentrations of 6-13 micromol/l) and liver copper concentrations averaged 98 mumol/kg fresh tissue. These data suggest that 'deficient', 'marginal' and 'adequate' ranges for serum copper concentrations should be 5, 5-8, and 8 micromol/l, respectively, and those for liver copper concentrations should be 60, 60-100, and 100 micromol/kg, respectively. SELENIUM: White muscle disease has been reported in young deer with blood and liver selenium concentrations of 84-140 nmol/l and 240-500 nmol/kg fresh tissue, respectively. No growth-rate response to selenium supplementation occurred in rising 1-year-old deer when blood selenium concentrations were less than 130 nmol/l, the range in which a growth-rate response would be expected in sheep. VITAMIN B12: Vitamin B12 concentrations in deer are frequently below 185 pmol/l without clinical or subclinical effects. No growth response was observed in young deer with vitamin B12 concentrations as low as 75-83 pmol/l. A growth response to cobalt/vitamin B12 supplementation occurs in lambs with serum vitamin B12 concentrations 336 pmol/l. CONCLUSIONS: Data that can be used to establish reference ranges for assessing trace element status in deer are limited. More robust reference values for farmed red deer need to be established through further studies relating biochemical data to health and performance.

Journal Article↗

The effect of long-acting injectable selenium formulations on blood and liver selenium concentrations and liveweights of red deer (Cervus elaphus).

AIM: To evaluate the efficacy of a new long acting injectable selenium ( Se ) formulation to increase the Se status and prevent Se deficiency in red deer. METHODS: Groups of weaned red deer (four stags and six hinds/group) grazing pastures containing <30 mg Se/kg DM were injected subcutaneously with either 0.5, 1.0 or 2.0 mg Se/kg as a new formulation of BaSeO4 (Deposel Multidose), 1.0mgSe/kg of a current formulation (Deposel), or not treated. Blood Se concentrations and liveweight were measured nine times at intervals over 377 and 270 days, respectively. RESULTS: Both formulations of Se elevated blood Se concentrations from 105 nmol/l pre-injection for at least 377 days with peak levels of 1894, 1395 and 818 nmol/l for high, medium and low doses of Deposel Multidose, respectively, at 73141 days, and 1508 nmol/l at 73-141 days for the medium dose of Deposel, which persisted at similar levels for the duration of the study. Deposel Multidose produced fewer and less severe subcutaneous tissue reactions than Deposel. Pastures contained 10 to 30 mg Se/kg DM. There was no significant difference in growth rate between treated and control deer. There was a significant (p<0. 01) linear relationship (y = 1.25x + 71.6, R2=0.86) between blood (x) and liver (y) Se concentrations in the range of 120 - 2100 nmol/l for blood concentrations, and 200 - 3000 nmol/kg for liver concentrations. CONCLUSION: Injections of BaSeO4 in both formulations studied were effective in increasing the Se status of deer but the new formulation produced fewer and less-severe tissue reactions. Young growing red deer appear less sensitive to Se deficiency as measured by weight gain, than sheep and cattle, suggesting that reference ranges for those species are not appropriate for deer. There was a linear correlation between blood and liver selenium concentrations.

Journal Article↗

Effect of an injectable microencapsulated Vitamin B12 on serum and liver Vitamin B12 concentrations in calves.

AIM: To evaluate the efficacy of a long-acting injectable microencapsulated formulation of Vitamin B12 in dairy calves. METHOD: Fifty calves, average liveweight 110kg, were randomly allocated to 5 groups of 10 animals and injected subcutaneously in the anterior neck with 0.12, 0.18, 0.24 and 0.3 mg Vitamin B12/kg liveweight using a formulation of microencapsulated Vitamin B12 in a lactide: glycolide copolymer. The untreated calves were injected with the same vehicle, without Vitamin B12. Subsequent changes in serum and liver Vitamin B12 concentrations were followed for 244 days. RESULTS: The microencapsulated Vitamin B12 significantly increased, then maintained serum and liver Vitamin B12 concentrations higher than those of untreated controls for at least 110 days. CONCLUSIONS: Injection of the microencapsulated Vitamin B12 at dose rates of 0.12 to 0.24 mg/kg liveweight will increase and maintain the Vitamin B12 status of calves for at least 110 days.

Journal Article↗

Changes in liver copper concentration of thoroughbred foals from birth to 160 days of age and the effect of prenatal copper supplementation of their dams.

OBJECTIVES: To monitor the change in liver copper concentration of Thoroughbred foals from birth to 160 days of age and to determine the effects of supplementation by two injections of copper edetate given to dams in late gestation on the liver copper concentration of their foals at birth. PROCEDURE: Ten mares pregnant to the same stallion were randomised into two groups on the basis of age, liver copper concentration and expected foaling date. The treatment group mares were given 100 mg and 250 mg copper edetate intramuscularly during the ninth and tenth months of gestation respectively. Foals had liver biopsies taken weekly in the first month of life, then monthly for four months. Foals were euthanased at 160 days of age; liver samples were taken and the copper concentrations were determined. RESULTS: Two distinct patterns of age dependent decline in liver copper concentration were evident. The mean (+/- SD) liver copper concentration of the foals was high at birth (374 +/- 130 mg/kg DM), and for seven it declined to adult values by 160 days of age (21 +/- 6 mg/kg DM). In three foals the decline was at a slower rate than in the other seven and at 160 days of age the mean concentration was 162 +/- 32 mg/kg DM. Repeated measures analysis showed significant differences between each biopsy (P < 0.01) and between 'normal' and 'accumulator' foals (P < 0.002). Copper injections given to mares in late pregnancy had no effect on the liver copper concentration of foals at birth. CONCLUSIONS: The significance of the two patterns of age dependant decline in liver copper concentration is unknown. Parenteral copper supplementation of the dam in late gestation had no effect on the liver copper concentration of the foal at birth.

Aging↗

An evaluation of the efficacy of injectable microencapsulated vitamin B12 in increasing and maintaining the serum and liver vitamin B12 concentrations of lambs.

AIM: To develop a long-acting Vitamin B12 injection to prevent Co deficiency in sheep. METHODS: Formulations of microencapsulated Vitamin B12 in lactide-glycolide polymers were injected intramuscularly or subcutaneously into the anterior neck region of groups of 10 lambs and their efficacy determined from changes in serum and liver Vitamin B12 concentrations. RESULTS: The 95:5 lactide glycolide and the 100 lactide formulations containing more than 12.5% Vitamin B12 w/w significantly increased and maintained serum Vitamin B12 concentrations for at least 210 days as well as liver Vitamin B12 concentrations in treated lambs when compared with untreated controls. CONCLUSIONS: Injections of microencapsulated Vitamin B12 in lactide/glycolide copolymers are able to increase and maintain the Vitamin B12 status of lambs for at least 210 days. CLINICAL SIGNIFICANCE: Another option for the prevention of Co deficiency in sheep is now available using a long acting injectable Vitamin B12.

Journal Article↗

The effect of increasing the Vitamin B12 status of Romney ewes on foetal liver Vitamin B12, milk Vitamin B12 and liver Vitamin B12 concentrations in suckling lambs.

AIM: To determine the effect of increasing the Vitamin B12 status of the ewe on the Vitamin B12 supply to the suckling lamb. METHODS: The Vitamin B12 status of the ewe was increased during gestation and lactation by three injections of a long-acting preparation of Vitamin B12 microencapsulated in an organic acid polymer. The Vitamin B12 status of the ewes and suckling lambs was assessed from changes in serum and liver Vitamin B12 concentrations. RESULTS: Compared to untreated animals, serum and liver Vitamin B12 concentrations of the treated ewes were increased at least 70% during gestation. Foetal liver Vitamin B12 concentrations were increased 270%. Over the lactation, ewe serum and milk Vitamin B12 concentrations were increased at least 200% and 44%, respectively. The liver Vitamin B12 stores of the newborn lambs from Vitamin B12-treated ewes were depleted within 58 days. There were no significant differences in the serum Vitamin B12 concentrations of suckling lambs from Vitamin B12-treated and untreated ewes. CONCLUSION: Ewes with a high Vitamin B12 status will ensure an adequate supply of Vitamin B12 to their lambs for at least the first 30 days of life. CLINICAL SIGNIFICANCE: In flocks grazing Co-deficient pastures, treating ewes with a long-acting Vitamin B12 supplement at mating will prevent Vitamin B12 (Co) deficiency in ewes, as well as their lambs, until they can be treated at tailing at 4-6 weeks of age.

Journal Article↗

Content and distribution of macro- and micro-elements in the body of pasture-fed young horses.

OBJECTIVE: To determine the content and distribution of Na, K, Ca, P, Mg, S, Cu, Mn, Fe and Zn in the body of pasture-fed young horses and then use a factorial model to calculate the dietary mineral requirements for growth. PROCEDURE: Twenty-one foals were killed at about 150 days of age and the organs, soft tissues, skin and bones and a sample of muscle were dissected out and weighted. The mineral concentrations of elements in all soft tissues and bones were measured by inductively coupled emission spectrometry. The total mineral element composition associated with a tissue was determined from the weight of tissue and its mineral element concentration. RESULTS: Expressed as a percent of total body mineral elements, muscle contained 20% Na, 78% K, 32% Mg, 62% Cu, 36% Mn and 57% Zn, bone contained 47% Na, 99% Ca, 81% P, 62% Mg, 30% Mn and 28% Zn while the organs accounted for a smaller percentage ranging from 0.06% for Ca to 26% for Fe. In liver Cu accounted for 9.2% of total body Cu. Each kilogram of empty body weight was associated with 1.0 g Na, 2.5 g K, 17.1 g Ca, 10.1 g P, 0.4 g Mg, 1.1 mg Cu, 0.39 mg Mn, 52.5 mg Fe and 21.4 mg Zn. CONCLUSION: The mineral element content of body weight gain is a component used in the factorial model to determine dietary mineral element requirements for growth. The calculated dietary mineral requirements, expressed per kg dry matter, for a 200 kg horse gaining 1.0 kg/day were 1.0 g Na, 2.1 g K, 4.6 g Ca, 3.5 g P, 0.7 g Mg, 4.5 mg Cu and 25 mg Zn.

Animal Feed↗

Concentrations of macro- and micro-elements in the milk of pasture-fed thoroughbred mares.

OBJECTIVE: To determine the changes in Ca, P, Mg, Na, K, S, Cu, Fe and Zn concentrations of milk during the lactation in pasture-fed Thoroughbred mares and then calculate the dietary mineral requirements of the sucking foal and the lactating mare. PROCEDURE: Milk was sampled on days 1, 3, 7, 14, 21, 28 and at various times between 55 to 65, 85 to 95 and 135 to 150 days after parturition from 21 pasture-fed mares. The concentrations of macro- and micro-elements in the milk were determined by inductively coupled plasma emission spectrometry. RESULTS: Concentrations (mg/L) of these elements were highest in colostrum (Mg 302, Na 561, K 955, S 1035, Cu 0.76, Fe 0.79 and Zn 5.5) except for Ca (1245) and P (895), which where highest on day 7. The mean milk mineral element concentrations (mg/L) over days 55 to 150 were Ca 843, P 543, Mg 47, Na 120, K 590, S 219, Cu 0.19, Fe 0.34 and Zn 2.1. The mean plasma element concentrations (mg/L) over the same period were Ca 120, P 77.1, Mg 17.0, Na 3110, K 168, S 983, Cu 1.1, Fe 1.5 and Zn 0.49. Concentration gradients between plasma and milk were observed and, in the case of Ca, P, Mg, K and Zn, their concentrations in milk were greater than those in plasma, while a reverse situation was observed for Na, S, Cu and Fe. CONCLUSION: With the exception of Ca and P, the highest concentrations of mineral elements were observed in the colostrum. The nursing foal should have access to good pasture or creep feed, because the intakes of Ca, P and Cu from milk may be less than optimum to meet the daily mineral element requirements.

Animal Feed↗

Significance of amount and form of dietary selenium on blood, milk, and casein selenium concentrations in grazing cows.

Organic selenized yeast enriched with selenoamino acids or inorganic sodium selenate (Na2SeO4) was administered per os three times weekly as a drench for 133 d to previously unsupplemented cows that were grazing low Se pastures. Treatment groups received the equivalent of 2 or 4 mg of Se/d of either supplement form. Control cows did not receive a drench. Samples of blood and milk were collected regularly throughout the trial. Selenium concentrations in blood, milk, casein, and liver and glutathione peroxidase activity in blood and liver are reported as responses per milligram of Se intake. Mean blood Se concentrations in treated cows increased steadily and, by d 133, were 4.7 to 8.8 times that in controls. Selenized yeast was 2 to 3 times more effective than was Na2SeO4, and low Se intakes were 27% more efficient per milligram of Se administered than were high Se intakes at increasing milk Se concentration. Casein Se content mirrored that of milk; among all treated and control cows and throughout the trial, the molar ratio of Se in casein as a percentage of the Se in whole milk was constant at 71 +/- 1.2%. The Se concentration in liver biopsies taken on d 133 was indicative of total Se intake during the trial and ranged from 920 to 3920 nmol of Se/kg of fresh weight. These results demonstrate the differing efficacy of organic and inorganic Se dietary supplements to increase dairy cow Se status and to enhance Se content of milk and casein.

Animals↗

Pharmacologic intervention during the acute bleeding episode.

The risk of recurrent variceal bleeding after an acute episode of bleeding has been controlled in significant with rebleeding rates as high as 80% between one and two years. Pharmacologic therapy has a definite role in the prevention of recurrent variceal bleeding and should be started as soon as the acute bleeding event has been controlled. Serial hemodynamic measurements are critical for success. Non-selective beta-blocker therapy is a reasonable first line approach followed by the addition of a long-acting nitrate for patients not achieving a 20% reduction in the hepatic venous pressure gradient. Most patients will require combination pharmacotherapy or combined endoscopic therapy with pharmacotherapy.

Acute Disease↗

Pharmacological prevention of rebleeding.

Pharmacologic therapy used during acute variceal bleeding may control the bleeding episode, minimized transfusion requirements, and prevent early rebleeding. Several options for pharmacologic therapy exist in this setting and include: vasopressin in combination with nitroglycerin, terlipressin, somatostatin, and octreotide. Metoclopramide and domperidone may also be useful but require additional study. At present, octreotide, administered intravenously as soon as variceal bleeding is suspected, is favored.

Adrenergic beta-Antagonists↗